TREML4 polymorphisms increase the mRNA in blood leukocytes in the progression of atherosclerosis.

Victor Hugo Rezende Duarte\textsuperscript{a*}, Marina Sampaio Cruz\textsuperscript{a}, Adriana Bertolami\textsuperscript{b}, Mario Hiroyuki Hirata\textsuperscript{c}, Rosario Dominguez Crespo Hirata\textsuperscript{c}, André Ducati Luchessi\textsuperscript{a} & Vivian Nogueira Silbiger\textsuperscript{a*}.

\textsuperscript{a}Department of Clinical and Toxicological Analyses, Federal University of Rio Grande do Norte. General Cordeiro de Farias Av., Natal, Rio Grande do Norte, 59012-570, Brazil,

\textsuperscript{b}Dyslipidemia Medical Section, Dante Pazzanese Institute of Cardiology, Av. Dr. Dante Pazzanese, 500, 04012-909, São Paulo, Brazil.

\textsuperscript{c}Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo. 580 B17 Lineu Prestes Av., Butantan,05508-900. Sao Paulo, Brazil.

*Corresponding authors
E-mail address; V.H.R.D (email: victorhugorezendeduarte@gmail.com) and V.N.S. (email: vivian.silbiger@ufrn.br)

Address: Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil. Avenue General Gustavo Cordeiro de Farias, S/N, Natal, Rio Grande do Norte CEP: 59014-520, Brazil
### Supplementary table 1. Use of medications in subclinical Atherosclerosis and controls.

| Medications   | Control (133) | SA (207) | p-value |
|---------------|---------------|----------|---------|
| Ezetimibe, %  | 6.80 (9)      | 12.1 (25)| 0.111   |
| Statins, %    | 55.6 (74)     | 73.4 (152)| 0.001  |
| Diuretics, %  | 37.6 (50)     | 49.8 (103)| 0.028  |
| ACEIs, %      | 39.1 (52)     | 49.6 (97)  | 0.159  |
| Vasodilators, %| 0.8 (1)    | 1.9 (4)    | 0.378  |
| Fibrate, %    | 5.3 (7)       | 2.4 (5)    | 0.165  |
| Beta-Blockers, %| 30.1 (40)| 30.0 (62)  | 0.981  |
| ASA, %        | 33.1 (44)     | 40.1 (83)  | 0.192  |
| Spironolactone, %| 3.8 (5)  | 3.9 (8)    | 0.961  |

Data are shown as the percentage and number of patients in parentheses. The variables were compared by the Chi-squared test. ACEIs - angiotensin-converting enzyme inhibitors, ASA - acetylsalicylic acid.

### Supplementary Table 2. Use of medications by patients with LV dysfunction after MI.

| Medications              | LVEF > 40% (14) | LVEF ≤ 40% (14) | p-value |
|--------------------------|-----------------|-----------------|---------|
| Antihypertensive, %      | 100 (14)        | 100 (14)        | 0.999   |
| Statins, %               | 100 (14)        | 100 (14)        | 0.999   |
| Platelet aggregation inhibitors, % | 100 (14) | 100 (14) | 0.999   |
| Diuretics, %             | 28.6 (4)        | 71.4 (10)       | 0.023   |
| Antidiabetics, %         | 21.4 (3)        | 71.4 (10)       | 0.008   |

Data are shown as the percentage and number of patients in parentheses. The Chi-squared test compared the variables.